Autres langues Amarin Corporation plc

Actions

AMRN

US0231114044

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 31/07/2026 Varia. 5j. Varia. 1 janv.
14,26 USD +0,21% Graphique intraday de Amarin Corporation plc +5,24% +2,19%

Autres langues

29/07 European Equities Traded in US as ADRs Ease in Wednesday Trading
29/07 Amarin Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
29/07 Amarin: Q2 Earnings Snapshot
29/07 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
15/07 Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
02/07 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
30/06 Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape 
30/06 Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
29/06 European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
23/06 Top cases on the US Supreme Court's docket
22/06 European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
18/06 European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading
09/06 European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
08/06 European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
05/06 Afternoon Meeting: Los datos de empleo complican la labor de la Fed
05/06 The Jobs Report Just Made the Fed's Life Harder
05/06 To infinity and beyond
04/06 Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
04/06 Top cases on the US Supreme Court's docket
04/06 Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
04/06 Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
28/05 European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
27/05 New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
27/05 Amarin Corporation plc Presents New REDUCE-IT Analysis At European Atherosclerosis Society Congress 2026
26/05 European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
Aucun résultat pour cette recherche